Matteo Tonietto

Matteo Tonietto

Auto-generated profile, based on publicly available information

Matteo Tonietto

Neuroscience and Rare Diseases Roche Pharma Early Research and Development, F. Hoffmann‐La Roche Ltd Basel Switzerland

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in Radiology
Verified
Journal Article
Closed access
Vito AG RiciglianoVito AG Ricigliano
Vito AG Ricigliano
EMEmanuele Morena
Emanuele Morena
ACAnnalisa Colombi
Annalisa Colombi
MTMatteo Tonietto
Matteo Tonietto
MHMariem Hamzaoui
Mariem Hamzaoui
BSBruno Stankoff
Bruno Stankoff
A combination of three-dimensional MRI and translocator protein PET demonstrated enlarged and inflamed choroid plexuses in patients with multiple sclerosis (MS), representing a potential imaging ma... Background Choroid plexuses (CPs) have been suggested as a key gateway for inflammation in experimental autoimmune encephalitis, but in vivo evidence of their involvement in multiple sclerosis (MS)...

8 March 2019 in Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
JSJulia J. Schubert
Julia J. Schubert
MVMattia Veronese
Mattia Veronese
LMLivia Marchitelli
Livia Marchitelli
BBBenedetta Bodini
Benedetta Bodini
MTMatteo Tonietto
Matteo Tonietto
FTFederico E. Turkheimer
Federico E. Turkheimer
Cerebrospinal fluid (CSF) plays an important role in the clearance of solutes and maintenance of brain homeostasis. 11C-PiB PET was recently proposed as a tool for detection of CSF clearance alterations in Alzheimer’s disease. The current study seeks to investigate the magnitude of 11C-PiB PET signal in the lateral ventricles of an independent group of Alzheimer’s and mild cognitive impairment subjects. We have also evaluated multiple sclerosis as a model of disease with CSF clearance alterations without amyloid-beta tissue accumulation. Methods: A set of Alzheimer’s and mild cognitive impairment subjects and a set of multiple sclerosis subjects with matched healthy controls underwent MRI and dynamic 11C-PiB PET. Manual lateral ventricle regions of interest were generated from MRI data. PET data was analysed using a simplified reference tissue model with cerebellum or a supervised reference region, for the Alzheimer’s and multiple sclerosis datasets, respectively. Magnitude of 11C-PiB signal in the lateral ventricles was calculated as area under curve from 35 to 80 minutes and standard uptake value ratio (SUVR) from 50 to 70 minutes. Compartmental modelling analysis was performed on a separate dataset containing Alzheimer’s and matched healthy control data with an arterial input function to further understand the kinetics of the lateral ventricular 11C-PiB signal. Results: Analysis of variance revealed significant group differences in lateral ventricular SUVR across the Alzheimer’s, mild cognitive impairment, and healthy control groups (P = 0.004). Additional pairwise comparisons revealed significantly lower lateral ventricular SUVR in Alzheimer’s compared to healthy controls (p<0.001) and mild cognitive impairment (P = 0.029). Lateral ventricular SUVR was also significantly lower in multiple sclerosis compared to healthy controls (P = 0.008). Compartmental modelling analysis revealed significantly lower uptake rates of 11C-PiB signal from blood (P = 0.005) and brain tissue (P = 0.004) to the lateral ventricles in Alzheimer’s compared to healthy controls. This analysis also revealed significantly lower clearance of 11C-PiB signal out of the lateral ventricles in Alzheimer’s compared to healthy controls (P = 0.002). Conclusion: Overall, these results indicate that dynamic 11C-PiB PET can be used to observe pathological changes in cerebrospinal fluid dynamics and that cerebrospinal fluid-mediated clearance is reduced in Alzheimer’s disease and multiple sclerosis compared to healthy controls.

26 March 2014 in Journal of Cerebral Blood Flow & Metabolism
Verified
Journal Article
Open access
GRGaia Rizzo
Gaia Rizzo
MVMattia Veronese
Mattia Veronese
MTMatteo Tonietto
Matteo Tonietto
PZPaolo Zanotti-Fregonara
Paolo Zanotti-Fregonara
FTFederico Turkheimer
Federico Turkheimer
ABAlessandra Bertoldo
Alessandra Bertoldo
The positron emission tomography radioligand [11C]PBR28 targets translocator protein (18 kDa) (TSPO) and is a potential marker of neuroinflammation. [11C]PBR28 binding is commonly quantified using a two-tissue compartment model and an arterial input function. Previous studies with [11C]HRJ-PK11195 demonstrated a slow irreversible binding component to the TSPO proteins localized in the endothelium of brain vessels, such as venous sinuses and arteries. However, the impact of this component on the quantification of [11C]PBR28 data has never been investigated. In this work we propose a novel kinetic model for [11C]PBR28. This model hypothesizes the existence of an additional irreversible component from the blood to the endothelium. The model was tested on a data set of 19 healthy subjects. A simulation was also performed to quantify the error generated by the standard two-tissue compartmental model when the presence of the irreversible component is not taken into account. Our results show that when the vascular component is included in the model the estimates that include the vascular component (2TCM-1K) are more than three-fold smaller, have a higher time stability and are better correlated to brain mRNA TSPO expression than those that do not include the model (2TCM).

3 May 2023 in Annals of Neurology
Verified
Journal Article
Open access
MHMariem Hamzaoui
Mariem Hamzaoui
JGJeanne Garcia
Jeanne Garcia
GBGiacomo Boffa
Giacomo Boffa
ALAndrea Lazzarotto
Andrea Lazzarotto
MAMartina Absinta
Martina Absinta
BSBruno Stankoff
Bruno Stankoff
Objective: To determine the prognostic value of persisting neuroinflammation in multiple sclerosis (MS) lesions, we developed a 18 kDa‐translocator‐protein‐positron emission tomography (PET) ‐based classification of each lesion according to innate immune cell content and localization. We assessed the respective predictive value of lesion phenotype and diffuse inflammation on atrophy and disability progression over 2 years.Methods: Thirty‐six people with MS (disease duration 9 ± 6 years; 12 with relapsing–remitting, 13 with secondary‐progressive, and 11 with primary‐progressive) and 19 healthy controls (HCs) underwent a dynamic [18F]‐DPA‐714‐PET. At baseline and after 2 years, the patients also underwent a magnetic resonance imaging (MRI) and neurological examination. Based on a threshold of significant inflammation defined by a comparison of [18F]‐DPA‐714 binding between patients with MS and HCs, white matter lesions were classified as homogeneously active (active center), rim‐active (inactive center and active periphery), or nonactive. Longitudinal cortical atrophy was measured using Jacobian integration.Results: Patients with MS had higher innate inflammation in normal‐appearing white matter (NAWM) and cortex than HCs (respective standardized effect size = 1.15, 0.89, p = 0.003 and < 0.001). Out of 1,335 non‐gadolinium‐enhancing lesions, 53% were classified as homogeneously‐active (median = 17 per patient with MS), 6% rim‐active (median = 1 per patient with MS), and 41% non‐active (median = 14 per patient with MS). The number of homogenously‐active lesions was the strongest predictor of longitudinal changes, associating with cortical atrophy (β = 0.49, p = 0.023) and Expanded Disability Status Scale (EDSS) changes (β = 0.35, p = 0.023) over 2 years. NAWM and cortical binding were not associated to volumetric and clinical changes.Interpretation: The [18F]‐DPA‐714‐PET revealed that an unexpectedly high proportion of MS lesions have a smoldering component, which predicts atrophy and clinical progression. This suggests that following the acute phase, most lesions develop a chronic inflammatory component, promoting neurodegeneration and clinical progression. ANN NEUROL 2023;94:366–383

4 November 2019 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
SASylvain Auvity
Sylvain Auvity
MTMatteo Tonietto
Matteo Tonietto
FCFabien Caillé
Fabien Caillé
BBBenedetta Bodini
Benedetta Bodini
MBMichel Bottlaender
Michel Bottlaender
BSBruno Stankoff
Bruno Stankoff

13 September 2022 in Brain
Verified
Journal Article
Closed access
PDF file
MTMatteo Tonietto
Matteo Tonietto
EPEmilie Poirion
Emilie Poirion
ALAndrea Lazzarotto
Andrea Lazzarotto
Vito AG RiciglianoVito AG Ricigliano
Vito AG Ricigliano
CPCaroline Papeix
Caroline Papeix
BSBruno Stankoff
Bruno Stankoff
In multiple sclerosis, spontaneous remyelination is generally incomplete and heterogenous across patients. A high heterogeneity in remyelination may also exist across lesions within the same individual, suggesting the presence of local factors interfering with myelin regeneration. In this study we explored in-vivo the regional distribution of myelin repair and investigated its relationship with neurodegeneration. We first took advantage of the myelin binding property of the amyloid radiotracer [11C]PiB to conduct a longitudinal [11C]PiB positron emission tomography study in an original cohort of 19 participants with a relapsing-remitting form of multiple sclerosis, followed-up over a period of 1-4 months. We then replicated our results on an independent cohort of 40 people with multiple sclerosis followed-up over one year with magnetization transfer imaging, an MRI metrics sensitive to myelin content. For each imaging method, voxel-wise maps of myelin content changes were generated according to modality-specific thresholds. We demonstrated a selective failure of remyelination in periventricular white matter lesions of people with multiple sclerosis in both cohorts. In both the original and the replication cohort, we estimated that the probability of demyelinated voxels to remyelinate over the follow-up increased significantly as a function of the distance from ventricular cerebro-spinal fluid. Enlarged choroid plexus, a recently discovered biomarker linked to neuroinflammation, was found to be associated with the periventricular failure of remyelination in the two cohorts (r=-0.79, p = 0.0018; r=-0.40, p = 0.045 respectively), suggesting a role of the brain-cerebrospinal fluid barrier in affecting myelin repair in surrounding tissues. In both cohorts, the failure of remyelination in periventricular white matter lesions was associated with lower thalamic volume (r = 0.86, p < 0.0001; r = 0.33; p = 0.069 respectively) an imaging marker of neurodegeneration. Interestingly, we also showed an association between the periventricular failure of remyelination and regional cortical atrophy that was mediated by the number of cortex-derived tracts passing through periventricular white matter lesions, especially in patients at the relapsing-remitting stage. Our findings demonstrate that lesion proximity to ventricles is associated with a failure of myelin repair and support the hypothesis that a selective periventricular remyelination failure in combination with the large number of tracts connecting periventricular lesions with cortical areas is a key mechanism contributing to cortical damage in multiple sclerosis.